Detalles de la búsqueda
1.
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Breast Cancer Res Treat;
2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38767786
2.
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Breast Cancer;
2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38642245
3.
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
JCO Precis Oncol;
8: e2300647, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38635933
4.
Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.
Breast Cancer;
31(1): 53-62, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37882974
5.
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
J Immunother Cancer;
11(9)2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37709297
6.
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Breast Cancer;
30(6): 943-951, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37486454
7.
HDR-brachytherapy for accelerated partial breast irradiation: Long-term experience from a Japanese institution.
J Contemp Brachytherapy;
15(1): 1-8, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36970436
8.
Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.
Cancer Med;
12(9): 10280-10293, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36916728
9.
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
Eur J Cancer;
168: 108-118, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35500404
10.
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
BMC Cancer;
21(1): 1269, 2021 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34819039
11.
Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214.
Cancers (Basel);
13(17)2021 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-34503209
12.
Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
BMC Cancer;
21(1): 795, 2021 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34238257
13.
Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).
Breast Cancer;
28(5): 1023-1037, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33811599
14.
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Breast Cancer Res Treat;
188(1): 117-131, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33763789
15.
Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast Cancer.
Oncologist;
26(4): e686-e693, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33321004
16.
Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report.
Immunotherapy;
13(3): 189-194, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33225795
17.
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Breast Cancer Res Treat;
180(1): 135-146, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31953696
18.
Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples.
Sci Rep;
9(1): 13343, 2019 09 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-31527824
19.
Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.
Transl Oncol;
12(10): 1386-1394, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31382135
20.
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.
Cancer Med;
8(12): 5468-5481, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31361400